Want to join the conversation?
$WAT 2Q15 PR: SG&A expenses were $122.66MM vs. $131.93MM in 2Q14. R&D expenses were $30.56MM vs. $26.98MM in 2Q14. As of July 4, 2015, WAT had cash and cash equivalents and investments of $2208.89MM vs. $2055.39MM at Dec. 31, 2014. Total equity was $1932.56MM at July 4, 2015 vs. $1894.67MM at Dec. 31, 2014.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.